Plain-English translation of NCT01639508 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called in patients with advanced non-small cell lung cancer that has specific genetic changes—like RET, ROS1, or NTRK fusions, or increased MET or AXL activity. These genetic changes cause cancer cells to grow faster. The medication is designed to block the proteins these genes produce and stop cancer cells from spreading and forming new blood vessels that feed the tumor.
This medication has already shown promise in treating other types of cancer, such as thyroid and prostate cancer. This trial is checking whether it can also shrink lung cancers in people with these specific genetic changes and what side effects to expect.
You likely qualify if…
You likely don't qualify if…
You would take as an oral pill on a regular schedule while being monitored by the research team. You would attend regular clinic visits for blood tests, imaging scans to measure your tumor, and check-ins about how you are tolerating the medication and any side effects. The trial has different groups based on your specific genetic change, and some participants may have had prior treatment with other medications before joining.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States